Table 3 Metabolic parameters at euthanization

ΔFat mass (termination-treatment start) (g)^c

− 3.9 (± 3.7)^†

− 0.2 (± 6.18)

− 5.6 (± 3.3)^†

7.7 (± 3.4)^*,¤

ΔLean mass (termination-treatment start) (g)

12.3 (± 9.5)

10.7 (± 7.9)

6.3 (± 9.0)^†

19.1 (± 3.5)^¤

Epididymal fat depot (g)

1.4 (± 0.3)^#,†

2.6 (± 0.5)^*

1.1 (± 0.4)^#

2.3 (± 0.4)^*,¤

Liver weights (g/100g body weight)

2.9 (± 0.2)^¤,†

5.3 (± 0.4)^*,†

5.5 (± 0.4)^*,†

4.6 (± 0.5)^*,#,¤

Liver TG (µmol/g)^a

7.4 (± 1.9)^#,¤

14.4 (± 4.5)^*,¤

48.1 (± 16.4)^*,#,†

14.3 (± 4.8)^*,¤

Liver cholesterol (µmol/g)^a

5.6 (± 1.4)^#,¤,†

70.9 (± 14.3)^*

72.8 (± 13.2)^*

87.3 (± 14.9)^*

Liver glycogen (µmol/g)

245.6 (± 145.4)^¤

372.3 (± 93.8)

56.5 (± 94.8)^*,#,†

300.9 (± 51.5)^¤

Plasma 3-β-hydroxybutyrate (µmol/L)

406.5(± 257.2)^¤

464.3(± 89.8)^¤

3750(± 2150)^*,#,†

451.8(± 148.5)^¤

ΔHbA1c (%)^c

− 0.2 (± 0.2)^¤

− 0.1 (± 0.2)

2.0 (± 0.7)^*,†

− 0.6 (± 0.4)^¤

Endogenous insulin (RIIE)^a

265.5 (± 295.2)

472.3 (± 406.5)^¤

97.7 (± 110.4)^#

NA

Exposure HI (pM)

NA

NA

NA

246.5 (± 163.1)

Plasma free fatty acids^a (mmol/L)

0.7 (± 0.5)^¤

0.8 (± 0.5)^¤

2.0 (± 1.3)^*,#

1.0 (± 0.4)

Plasma VLDL-TG (mg/dL)^a

134.1 (± 61.8)^#,¤,†

256.9 (± 36.5)^*,¤

1074.0 (± 389.1)^*,#,†

247.0 (± 75.2)^*,¤

Plasma total cholesterol (mg/dL)^a

122.1 (± 18.3)

237.1 (± 25.1)^*

405.7 (± 75.6)^*,#,†

233.5 (± 19.0)^*,¤

Plasma LDL-C (mg/dL)^a

37.8 (± 22.9)^¤

24.3 (± 3.4)^¤

79.4 (± 29.0)^*,#,†

28.6 (± 4.7)^¤

Plasma HDL-C (mg/dL)

46.9 (± 22.3)^#,†

130.7 (± 22.4)^*,¤

50.5 (± 39.5)^#,†

124.8 (± 9.3)^*,¤

Alanine aminotransferase (ALAT)^b (U/L)

52.0 (± 21.5)

118.1 (± 53.3)

359.3 (± 250.0)

236.0 (± 88.5)

Aspartate aminotransferase (ASAT)^b (U/L)

50.0 (± 23.8)

51.4 (± 21.4)

109.1(± 46.8)

83.1 (± 47.9)

Plasma haptoglobin^a (g/L)

1.7 (± 1.4)^¤

0.9 (± 0.3)^¤

12.3 (± 6.0)^*,#,†

0.9 (± 0.1)^¤